.
MergerLinks Header Logo

New Deal


Announced

Hildred Capital-backed Crown Laboratories to acquire StriVectin from L Catterton.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Cosmetics

Domestic

skincare products

Private Equity

Acquisition

Friendly

Majority

Private

Pending

Single Bidder

United States

Synopsis

Edit

Hildred Capital-backed Crown Laboratories, a developer and provider of skin care products, agreed to acquire StriVectin, a provider of specialty skincare products, from L Catterton, a private equity firm. Financial terms were not disclosed. "Partnering with StriVectin is an exciting and significant next step in diversifying and scaling our organization. StriVectin has assembled a truly impressive team, a proven business model, and a premier product portfolio that is beloved by its customers. We are particularly excited that Cori will be assuming a senior executive role at Crown, helping to guide the merged businesses, and we think the combined talents of both teams will enable us to accelerate growth across all our product areas. The addition of StriVectin to Crown's portfolio enriches our focus on partnering with our customers throughout their lifetime skin health journey," Jeff Bedard, Crown Laboratories CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US